Life Sciences Archive » February, 2014

Life Sciences - February, 2014

277 articles

• Merck Says DOJ Has Ended Its Multicountry FCPA Probe
• High Court Must Fix Claim Construction Rule Now, Teva Says
• Actelion Settles Row Over Giving Drugs To Generics Makers
• FDA Updates Guidance On Avoiding Off-Label Promotion
• Pa. High Court's Design Ruling Revives Fen-Phen Suit
• Female Powerbrokers Q&A: Covington's Christine Haskett
• Female Powerbrokers Q&A: Holland & Knight's Anita Mosner
• FCA Suits Over Poor Drug Quality Are Down But Not Out
• Amarin Sues FDA Over Vascepa Market Exclusivity Denial
• Handful Of Banner Deals Define M&A In February
• Ex-SAC Manager Martoma Wants Conviction Thrown Out
• Takeda Accuses Watson Of Stepping On Gout Drug Patents
• Boiron Ducks Class Cert. In Suit Over Flu Remedy Label
• Amgen Anniversary Brings New Battle To Supreme Court
• Judge Reverses Precedex Patent Invalidation Following Deal
• Santaris Can't Skirt Infringement Claim In Isis Patent Row
• Health Care Orgs Call On FDA To Stop Painkiller Launch
• DOJ Skittish About Supreme Court Review Of FCA Pleading
• Omnicare Pays $4.2M To End FCA Suit Over Amgen Kickbacks
• Bulk Of $4M Fen-Phen Referral Fee Award Upheld On Appeal
• China Anti-Bribery Rules Raise Questions For Life Sciences
• FDA, EMA Back Safety Of Diabetes Drugs Targeted In MDL
• FRCP Discovery Amendments Prove Highly Controversial
• Sanofi Sues Watson, Glenmark Over Planned Multaq Generics
• W.Va. Plavix Ad Claims Remanded To State Court
• Meda Sues Perrigo, Impax Over Generic Nasal Spray
• Female Powerbrokers Q&A: Buchalter's Shawn Christianson
• Female Powerbrokers Q&A: Robins Kaplan's Hollis Salzman
• Bayer Snaps Up Chinese Over-The-Counter Drug Co.
• Ameritox Loses Sanctions Bid In Millennium Antitrust Suit
• Fed. Circ. Won't Rehear IP Suit Over Hanmi's Nexium Generic
• Stiefel Urges 11th Circ. To Reverse $1.5M Stock Sale Ruling
• Infusion Pump Co. Tells Jury Rival Had Plan To Infringe IP
• FDA Spied On Staff Without Considering Legal Risks: Report
• JPML Sends 12 Solodyn Antitrust Suits To Mass.
• Health Fraud Crackdown Nets $4.3B In 2013, Feds Say
• Celera Shareholders Win Class Cert.
• FDA Won't Change Medical Device Notification Rules
• GSK Can't Shake Calif. County's Avandia False Ad Claims
• Female Powerbrokers Q&A: Sedgwick's Stephanie Sheridan
• Female Powerbrokers Q&A: Pryor Cashman's Colleen Caden
• High Court Should Reverse 4th Circ.'s Flawed FCA Ruling
• Latham Snags Ex-Ropes & Gray White Collar Pro
• Brownstein Grows IP Team With 5 New Attys In Denver
• Armstrong, Supplement Co. Cycle Past False Marketing Suit
• J&J, Ethicon Sued Over Surgical Stapler Misfire
• Firms Kick Off Benicar Diarrhea Suits Against Daiichi
• LA Hospital Won't Bend In Ongoing Fight Over Knee Patents
• Shire Unit Settles Genzyme False Advertising Suit
• FDA Rips Research Co. Over Unapproved Electromagnet Trials
• Grand Jury Gets Last Word On Criminal Charges: High Court
• Salix Wins Jury Verdict In Breach Suit Over Napo Drug
• FDA Announces Recalls Of Trachea Tube, Catheter Devices
• The Unstoppable Trailblazer: Judge Shira Scheindlin
• Arent Fox Adds Ex-Novak Druce IP Pro In San Francisco
• FDA Blasts Another Indian Drug Firm Over Suspect Records
• Female Powerbrokers Q&A: Dentons' Kara Baysinger
• Female Powerbrokers Q&A: Winston & Strawn's Joan Fife
• The Continuing Saga Of Mayo V. Prometheus
• Deals Rumor Mill: BlackBerry, SoftBank, Chevron
• 9th Circ. Nixes Daw's Prosthetic Knee Antitrust Suit
• Total, Endo Units Hit With Vaginal Mesh Suit In Texas
• $6M Qui Tam Award Is Income, Not Capital Gain: Tax Court
• Zoloft False Ad Suit Time-Barred, Judge Finds
• Eli Lilly To Buy German Animal Health Business Lohmann
• J&J Hid Topamax Birth Defect Risks, Philly Jury Hears
• Rep. Urges Obama To Back Repeal Of ACA Medical Device Tax
• Fed. Circ. Upholds GSK Win Over Avodart Patent
• Female Powerbrokers Q&A: Bingham's Debra Fischer
• Female Powerbrokers Q&A: Nossaman's Nancy Smith
• Cinven Pays $915M For Clinical Research Co. Medpace
• Forest Investor Says $25B Actavis Offer Is Insufficient
• Par Pharma Loses Bid To Keep Appetite Drug Patent
• 5th Circ. Affirms Brand, Generic Wins In Reglan Suits
• FDA Chief Predicts Long Road For India Quality Reforms
• Ex-Texas Atty's Bid To Reverse 20-Year Sentence Rejected
• Miami New Times Cleared In Doping Clinic Privacy Suit
• Novartis Can't Shake $1.3M Zometa Verdict
• FDA Plans Overhaul Of Over-The-Counter Drug System
• GSK Cleared To Appeal RICO Questions In Avandia Suits
• CORRECTED: Endo Inks $193M Deal Over Off-Label Lidoderm Marketing
• Glaser Weil Lures McKool Atty Who Saved Ultramercial IP
• Lewis Brisbois Grabs Nelson Levine Pros For Pa. Expansion
• Female Powerbrokers Q&A: Ropes & Gray's Jane Goldstein
• Female Powerbrokers Q&A: Snell & Wilmer's Barb Dawson
• Law360 Life Sciences Editorial Advisory Board
• Pa. Appeals Court Won't Rehear Fixodent Evidence Dispute
• FDA Reverses Course On Exclusivity For New Drug Combos
• 9th Circ. Refuses To Revive Novartis Jaw Injury Suit
• Rotech Appeals Baker & McKenzie's Fee Award In Ch. 11 Case
• J&J Mesh Suits Belong In Federal Court, 10th Circ. Told
• Paul Hastings Nabs Pfizer's Top Compliance Officer
• Cipro Buyers Say Cos. Are Denying 'Stark Reality' Of Actavis
• Sports Clinic Owner Says MLB Ruined His Reputation
• Endo Puts Aside $520M For Vaginal Mesh Litigation
• Fed. Circ. Nixes Win For Takeda In Generic Prevacid Case
• J&J Blood Thinner Xarelto Caused Bleeding, Suit Says
• Deals Rumor Mill: Nokia, Merck, J. Jill
• Female Powerbrokers Q&A: Choate's Melissa Tearney
• Female Powerbrokers Q&A: Littler's Lee Schreter
• 9th Circ. Ruling Helps Nonparties Fight Abusive Discovery
• FDA Import Reforms To Fuel Fights Over Drugmaking Slip-Ups
• FTC Bags $2M False Ad Win Against Diabetes Supplement Co.
• Patent Trolls May Soon Threaten Drug Industry, Study Says
• USPTO Can't Be Blamed For Patent On 'Fraud' Stem Cells
• FDA Updates Guidance On Lab Data For New Drugs
• NY AG Takes Up Pay-For-Delay Mantle With Teva Deal
• CMS Urged To Abandon Medicare Part D Reform Proposal
• Reckitt, Ex-Exec Strike Deal Over 'Phony' $6M Severance
• $134M In Projected Colo. Marijuana Taxes Busts Estimates
• Clinical Trial Regulation Seeks Uniformity Across EU
• Hunton Atty's Alleged Stock Tip Sparks Criminal Probe
• MLB Drops Suit Against Drug Clinic That Supplied A-Rod
• Device Co. EndoGastric To Pay $5M In FCA Kickback Suit
• New Philly Mass Tort Program Created For Pelvic Mesh Suits
• Female Powerbrokers Q&A: Steptoe's Mimi Addy
• Female Powerbrokers Q&A: Ballard Spahr's Mary Mullany
• The Captain Of The Mother Court: Judge Loretta Preska
• Pfizer, GSK To Have Imported Drugs Fast-Tracked By FDA
• New Trial Denied, $1.9M Of Damages Added In Suture IP Row
• Shasta Wants Discovery To Proceed In Glucose Strip IP Case
• JPML Centralizes Lipitor Diabetes Suits In SC
• FDA Vows To Collaborate More With Indian Drug Regulators
• Fed. Circ. Won't Block Ossur Prosthetic Production In IP Row
• Stryker Pays $172M For German Surgical Device Co.
• France's Biosimilar Law May Set Trend Inside The EU
• Inter Partes Review: A Look At The Companies Under Attack
• Merck Sues Xellia Over Plan For Generic Anti-Fungal Drug
• J&J Wins 1st Vaginal Mesh Bellwether Trial
• BioChemics, D&O Insurer Battle Over SEC Subpoena Claim
• FDA Eyes Overhaul Of Risk Disclosure In Pharma Ads
• Female Powerbrokers Q&A: Kaye Scholer's Lori Leskin
• Female Powerbrokers Q&A: Hirschler's Courtney Paulk
• AdvaMed Plans Lobbying On Device Tax, Medicare Payments
• FDA Warns Baxter Over Infusion Pump Quality Controls
• Deals Rumor Mill: Tyson Foods, Peugeot, Starwood
• Latham-Led Actavis Pays $25B For Icahn-Backed Forest Labs
• Pharmacies Want Class Cert. In Pfizer Pay-For-Delay Case
• Med Cable Color Trademarks Can Be Restricted, TTAB Says
• FDA Again Rejects J&J, Bayer Blood Thinner Expansion
• Keryx, CEO Dodge Investor Class Action Over Cancer Drug
• J&J's Discovery Mishaps Barred From Vaginal Mesh Trial
• Medisca Recalls L-Citrulline Lots Amid FDA Warning
• FDA Outlines Feedback Process For Medical Device Approvals
• GSK Announcement May Change Industry Speaker Programs
• Injunction Likely In Case Over Diabetes Pill Ads, Judge Says
• Female Powerbrokers Q&A: Hughes Hubbard's Bassey
• Female Powerbrokers Q&A: Mitchell Silberberg's Coyoca
• P&G Dodges Denture Adhesive Claims In Pa. Court
• 6 Tips For Creating Effective Trial Graphics
• Boehringer Faces 2,000-Plus Pradaxa Injury Suits
• EU Lifts Duties On Chinese Pharma Chemical Imports
• Thermo Fisher Deal Shows Waivers, Timing Cut Antitrust Woes
• Diet Supplement Maker Says Inventor Peddling Its Product
• 10th Circ. Told J&J Pelvic Mesh Suits Belong In State Court
• Medtronic Seeks Reversal Of $393M Award In Valve IP Row
• Female Powerbrokers Q&A: Goodwin Procter's Sharton
• Female Powerbrokers Q&A: Levenfeld's Patti O'Connor
• Calculating Patent Term Adjustment Post-Novartis
• CMS Proposal Leaves Part D Protected Class Unprotected
• Australia Hits Pfizer With Antitrust Suit Over Lipitor
• Hogan Lovells Adds Ex-Kaye Scholer Corporate Partner
• Avanir Shareholders Can't Halt Proxy Vote
• Bill In Fla. Senate Would Legalize Medical Marijuana
• Teijin, Takeda Accuse Lupin Of Infringing Uloric Patent
• IP Challenges In India Being Exaggerated, ITC Told
• 3rd Circ. Mulls Class Cert. In J&J Reagent Antitrust Case
• FDA Hammers Active Ingredient Maker Over 'Severe Hazard'
• DEA Needs Warrants To Get Drug Records, Judge Says
• A Sign Of Long-Term Improvement Of ANDA Review Process
• Deals Rumor Mill: Carlyle, Blackstone, Giant Interactive
• Female Powerbrokers Q&A: Ballard Spahr's Emilie Ninan
• Female Powerbrokers Q&A: Steptoe's Lucinda Low
• Novartis Cancer Unit To Pay $8M To Settle Securities Row
• Biolitec Appeals $63M Sanction, CEO Arrest Order In IP Row
• UMass Takes Patent Dispute With Univ. Of Utah To High Court
• Amgen Hit With FDA Warning Over Drug-Device Combos
• FDA To Review AstraZeneca Diabetes Drug For Heart Risks
• 9th Circ. To Reconsider Its Remand Of Teva Painkiller Suit
• FDA Panel Says Data Don't Show Naproxen Is Safer NSAID
• Fla. Bill Would Let Pharmacies Sue Over Abusive Audits
• La. High Court Reins In State AG Medicaid Fraud Suits
• Mich. Drug Companies Now Less Immune Under Tort Reform
• Sens. Seek To Limit FDA's Health IT Regulatory Oversight
• Surgiview Owes $48M In OrthoTec Licensing Row, Jury Finds
• Seeger Weiss Says Vitamin Shoppe Trademark Suit Falls Short
• Catheter Connections Can't Shake IV-Valve Patent Suit
• Walgreen Misled Buyers Of Homeopathic Remedies, Suit Says
• Mallinckrodt Puts Down $1.3B To Acquire Cadence
• Senior Housing REIT Puts Up $1.1B For Boston Office Towers
• Female Powerbrokers Q&A: Ropes & Gray's Laurel FitzPatrick
• Female Powerbrokers Q&A: Baker Donelson's Donna Fraiche
• Medtronic Tells 10th Circ. Bone Device Suit Is Preempted
• Savient Pharma Unveils Ch. 11 Plan
• GAO, FDA Spar Over Progress On Drug Shortages
• Court Split Over Medical Device Claims Persists
• Roche Looks To Sink $2M Accutane Verdict On Appeal
• PhRMA Moves To Vanquish FTC Rule Targeting Drugmakers
• Pfizer Says 2nd Circ. Can't Review Lipitor FCA Suit
• Expert Testimony Barred In Denture-Adhesive Mass Tort
• Medicare Wrongly Paid $12M For Prisoners' Drugs, HHS Says
• Teva Under Federal Scrutiny Over Potential FCA Breaches
• Female Powerbrokers Q&A: FordHarrison's Tracey Jaensch
• Female Powerbrokers Q&A: McManis' Neda Mansoorian
• Prescription Fraud, Diversion Will Keep Spotlight In 2014
• Industry Groups Urge USTR To Step Up IP Pressure On India
• FDA Updates Disclosure Rules On Medical Device Changes
• J&J Wants Discovery Mishaps Barred From Vaginal Mesh Trial
• 5 Lessons Doctors Can Take From FDA's Big Stem-Cell Win
• How Supreme Court's Medtronic Ruling May Impact Licenses
• Forest Sues Glenmark Over Generic Fibromyalgia Treatment
• FDA Report Finds Big Drop In Drug Shortages
• La. Is Latest State To Demand Causation For Medicaid Fraud
• Myriad, Rival Strike Deal In Cancer-Test Patent Dispute
• Female Powerbrokers Q&A: McAndrews' Nabeela Rasheed
• Female Powerbrokers Q&A: Crowell's Ellen Dwyer
• Merck To Pay $100M To End NuvaRing Blood Clot Suits
• Judge Bars Whistleblower Claims In Liberty Medical Ch. 11
• FDA Details Expectations For Approval Of New Painkillers
• Pfizer Wants Professor's Report Out Of Birth Defect MDL
• Whistleblower Says Celgene Bribed Docs To Sell Cancer Meds
• Tighter Drug-Discount Rules Loom After 340B Report
• Genzyme's Cancer Drug IP Suit Can Proceed, Judge Says
• Fed. Circ. OKs Ruling Barring Generic Lyrica Until 2018
• Ex-SAC Manager Martoma Found Guilty Of Insider Trading
• Novartis Sues Dr. Reddy's Over ANDA For Cancer Drug
• Fla. Justices Mull Sublicense Terms In Blood Device IP Row
• NJ Court Won't Revive Malpractice Suit Over J&J Bias Case
• Female Powerbrokers Q&A: Wendel Rosen's Pamela Mintzer
• Female Powerbrokers Q&A: Hodgson Russ' Yalamanchili
• Litigation Costs Are In Your Control, So Take Control
• Martoma Awaits Verdict As Jury Mulls Defense Testimony
• FCA Perils Mount For Drugmakers As DOJ Gets Personal
• HHS Watchdog Says Rules For 340B Drug Program Unclear
• HHS Announces $90M Partnership For Anti-Bioterrorism Drug
• Abbott Hit With 5 AndroGel Suits In FDA Probe's Wake
• Nutrition Council Backs FTC Dissent On Health Ad Standard
• J&J Punished For Losing Evidence In Vaginal Mesh MDL
• Labeling Beverages And Supplements Post-FDA Guidance
• ArthroCare Investor Sues To Halt $2B Smith & Nephew Merger
• Apotex, Others Ask Fed. Circ. To Nix Allergan Latisse Patents
• Polsinelli Adds New FDA Practice Head In DC
• Myriad Genetics Puts Up $270M For Crescendo Bioscience
• Female Powerbrokers Q&A: Taft's Margaret Lawson
• Female Powerbrokers Q&A: Frankfurt's Barbara Shiers
• Ex-Redskins QB Shakes Prostate Drug False-Ad Suit
• Paul Hastings Helps Arrange $1B Accellent Financing Deal
• Martoma Jury Ends 1st-Day Deliberations With No Verdict
• Genentech, Roche Settle With PDL BioPharma Over Licensing
• BMS Says Genetic Technologies' DNA Tech Is Unpatentable
• 9th Circ. Urged To Reinstate Expert In Novartis Jaw Injury Suit
• Deals Rumor Mill: Liberty, Novartis, Blackstone
• Foley Hoag Lures Ropes & Gray IP Partner For Boston Office
• Drugmakers Tackle Biosimilars Oversight At FTC Forum
• FDA Can Regulate Stem Cell Treatments, DC Circ. Rules
• Negligent Drug Design Claims May Increase In Pa.
• Covidien's $2.5M Wage-And-Hour Settlement Gets Judge's OK
• Female Powerbrokers Q&A: Michelman's Mona Hanna
• Female Powerbrokers Q&A: Baker Donelson's Linda Klein
• Ferring Wins Lysteda Patent Trial Against Watson, Apotex
• Feds Urge Jury To Convict Ex-SAC Trader Martoma
• Biomet To Pay $56M To Settle Hip Replacement MDL
• In-House Counsel Name Client-Friendly Litigators
• GCs Name Best-Of-The-Best Attys
• Victim Of Steroid-Tainted Supplement Wins $4M In Settlements
• Merck To Spend Up To $2.3B In Ablynx Licensing Deal
• Deferred Sanctions Leave Hope For Takeda In Actos MDL
• Akerman Opens Chicago Office With Ulmer & Berne Team
• $3.3M Judgment Against Nature's Upheld In Prolab Row
• Wiley Rein Adds 3 Ex-BakerHostetler IP Attys In DC
• Smith & Nephew Pays $1.7B For Fellow Medical Device Maker
• Montagu Strikes $805M Deal For Rexam's Health Care Biz
• Female Powerbrokers Q&A: Holwell Shuster's Dorit Black
• Female Powerbrokers Q&A: Gibbons' Christine Amalfe
• Valeant Again Boosts Skin Care Biz With $500M PreCision Buy
• Patent Prosecution Lessons From Medtronic V. Edwards
• 1st Circ. Holds FCA Relator's Feet To The Rule 9(b) Fire